文献速递肾小球疾病慢性肾脏病

肾素-血管紧张素-醛固酮系统抑制剂在IgA肾病中的影响:随机对照试验的荟萃分析

The Impact of Renin-Angiotensin-Aldosterone System Inhibitors in IgA Nephropathy: A Meta-Analysis of Randomized Controlled Trials.
PubMed 文献 · Clin J Am Soc Nephrol · 2026-08-12

结果显示单用RAASi治疗患者年均eGFR下降斜率为-4.5 ml/min/1.73m²(95%CI -5.3至-3.8),提示不足以延缓ESKD风险,需疾病修饰治疗。

要点

  • 单用最大耐受剂量RAASi患者年均eGFR下降-4.5 ml/min/1.73m²
  • 该下降速率可能无法限制高危IgA肾病患者的ESKD风险
  • 需疾病修饰治疗以有效保护肾功能

核心结论

  • 最大耐受剂量RAASi单药治疗不足以充分减缓高危IgA肾病患者的eGFR下降速率,患者仍面临ESKD风险。

研究设计与样本

  • 荟萃分析纳入报告eGFR下降斜率且包含最大耐受剂量RAASi治疗臂的随机对照试验。

主要发现

  • 汇总数据分析显示,单用RAASi治疗参与者平均年eGFR斜率下降为-4.5 ml/min per 1.73 m²(95%CI -5.3至-3.8)。

关键数值与推荐

  • 高危IgA肾病患者年度eGFR下降一般需维持在≤1 ml/min per 1.73 m²以降低ESKD风险。
  • 单用RAASi治疗年均eGFR下降-4.5 ml/min per 1.73 m²(95%CI -5.3至-3.8)。

临床怎么用

  • 高危IgA肾病患者单用最大耐受剂量RAASi不足以充分延缓肾功能下降,应考虑联合疾病修饰治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Standard-of-care therapy for IgA nephropathy has historically relied on renin-angiotensin-aldosterone system inhibitors. Current treatment goals aim to slow eGFR decline to reduce the risk of ESKD. Analysis of renin-angiotensin-aldosterone system inhibitor therapy alone found an eGFR decline of -4.5 ml/min per 1.73 m 2 per year, which may not limit ESKD risk. BACKGROUND: IgA nephropathy is a chronic autoimmune kidney disease characterized by deposition of immune complexes in the glomeruli, leading to inflammation and progressive, irreversible, kidney damage. Patients with IgA nephropathy face a lifetime risk of ESKD, and an associated increase in mortality unless their annual eGFR decline is generally maintained at or below 1 ml/min per 1.73 m 2 . The current standard of care in IgA nephropathy involves supportive CKD therapies, notably renin-angiotensin-aldosterone system inhibitors (RAASi). Importantly, the long-term effectiveness of RAASi in slowing IgA nephropathy disease progression remains uncertain. Meta-analyses of randomized controlled trials with comparable designs offer an opportunity to assess the impact of RAASi therapy on kidney function. Such analyses facilitate outcome comparisons across studies and may generate important evidence and contribute to informed clinical decision making. METHODS: A meta-analysis was conducted using randomized controlled trials that reported the slope of eGFR decline and included one arm receiving maximally tolerated doses of RAASi. The analysis aimed to evaluate the impact of RAASi therapy on kidney function in high-risk patients with IgA nephropathy. RESULTS: A systematic literature review of four databases returned 171 studies published between January 2006 and November 2024. Of these, ten included a control arm of participants with IgA nephropathy receiving maximized RAASi treatment ( N =1366) and reported eGFR annualized slope decline. Meta-analysis of the pooled data demonstrated a mean annual eGFR slope decline of -4.5 ml/min per 1.73 m 2 (95% confidence interval, -5.3 to -3.8) among participants treated with RAASi therapy alone. CONCLUSIONS: Treatment with maximally tolerated RAASi alone does not sufficiently slow the rate of eGFR decline in high-risk patients with IgA nephropathy, leaving patients at risk of ESKD. These findings underscore the need for disease-modifying therapies capable of effectively preserving kidney function, particularly in this predominantly young patient population.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Rastogi A, Sarkar M, Kawai K, et al. The Impact of Renin-Angiotensin-Aldosterone System Inhibitors in IgA Nephropathy: A Meta-Analysis of Randomized Controlled Trials. Clin J Am Soc Nephrol. 2026. PMID: 42584957. doi:10.2215/CJN.0000001130

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。